Clinical trial NCT05630859: Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.
Official title: A Phase 1/2, Observer-blind, Randomized, Placebo-controlled Multi-country Study to Assess Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Sexually Transmitted Diseases
Keywords: Neisseria gonorrhoeae
Safety
Efficacy
Sexually transmitted infection
Healthy adults 18 to 50 years of age
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2022-11-30
Enrollment: 1004
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: PREVENTION

Brief summary: The aim of this first time in human proof of concept (FTiH-PoC) study is to evaluate safety and reactogenicity, to demonstrate efficacy and to explore immunogenicity of GlaxoSmithKline's (GSK) Neisseria gonorrhoeae generalized modules for membrane antigens (GMMA) (NgG) investigational vaccine compared to placebo (saline).


Eligibility criteria: Inclusion Criteria:

Inclusion criteria for the dose-escalation safety lead-in part

* Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any study-specific procedure.
* Healthy participants as established by medical history, clinical examination, and laboratory assessment.
* A participant between and including 18 and 50 years of age at the time of informed consent.
* Female participants of non-childbearing potential may be enrolled in the study.
* Female participants of childbearing potential may be enrolled in the study if the participant:

  * has practiced adequate contraception for 1 month prior to study intervention administration, and
  * has a negative pregnancy test on the day of study intervention administration, and
  * has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration series.

Inclusion criteria for the efficacy PoC part

* Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any study-specific procedure.
* Healthy participants as established by:

  * For the 2 intensive safety monitoring subsets (i.e., first 30 HIV negative subjects per group followed by first 8 HIV positive subjects per group): medical history, clinical examination, and laboratory assessment.
  * For all the remaining participants: medical history, clinical examination.
* At risk for gonococcus infections based on sexual behavioral characteristics: this may include men having sex with men, pre-exposure prophylaxis for HIV users, individuals who engage in transactional sex participants with current or past STI diagnosis, participants at time of STI screening or seeking other STI services.
* A participant between and including 18 and 50 years of age at the time of informed consent. Transgender men and women, and other gender non-conforming people who identify themselves as neither men nor women may be enrolled into the study, based on their risk factors. For the purpose of this study, they will be followed up according to their biological sex (sex at birth), sexual orientation, and genital/sexual anatomy
* Participants of non-childbearing potential may be enrolled in the study. This includes transmen that have not undergone gender affirming surgery of their genitals.
* Participants of childbearing potential may be enrolled in the study if the participant:

  * has practiced adequate contraception for 1 month prior to study intervention administration, and
  * has a negative pregnancy test on the day of study intervention administration, and
  * has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration series.

Exclusion criteria:

1. Medical conditions Dose-escalation safety lead-in part

   * Any clinically significant biochemical laboratory abnormality.
   * Any other clinical condition as determined by the investigator, that may increase participant's risk due to study participation.
   * History of any reaction/hypersensitivity likely to be exacerbated by any component of the study intervention.
   * Confirmed or suspected immunosuppressive/immunodeficient condition, based on medical history and physical examination.
   * Hypersensitivity to latex.
   * Acute/chronic clinically significant pulmonary, cardiovascular, hepatic/renal functional abnormality, as determined by physical examination/laboratory tests.
   * Uncontrolled neurological disorders or seizures.
   * History of invasive meningococcal disease. Efficacy PoC part: HIV negative intensive safety monitoring, HIV negative full enrollment and for all remaining participants
   * Persons under guardianship or trusteeship.
   * Persons deprived of liberty.
   * Gonococcal infection identified within 14 days prior to randomization.
   * Any other clinical condition as determined by the investigator, that may increase participant's risk due to study participation.
   * History of severe allergic reactions and/anaphylaxis, or any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
   * Bleeding diathesis / any other condition that would contraindicate intramuscular administration.
   * Confirmed or suspected immunosuppressive/immunodeficient condition, based on medical history and physical examination.
   * Known seropositivity for HIV infection, regardless of viremia and CD4 cell count
   * Hypersensitivity to latex.
   * Acute/chronic clinically significant pulmonary, cardiovascular, hepatic/renal functional abnormality, as determined by physical examination/laboratory tests.
   * Recurrent history/uncontrolled neurological disorders or seizures.
   * History of invasive meningococcal disease.

   The exclusion criteria depicted above, and the following exclusions criterion applies only for the HIV positive participants (intensive safety monitoring subset and full enrollment of HIV positive participants):

   Seropositivity for HIV infection if:
   * CD4 cell count \< 350 cells/mm3 in the last 6 months
   * viral load \> 50cp/ml in the last 6 months
   * participant is not on antiretroviral therapy (ART) for \> 3 months or has switched from a different ART in the last 3 months.

   For both Intensive safety monitoring subset (first 30 HIV negative subjects per group and first 8 HIV positive subjects per group) these criteria apply:

   Any clinically significant hematological/biochemical laboratory abnormality.
2. Prior/Concomitant therapy Applicable for both the dose-escalation safety lead-in part and the PoC part

   * Use of any investigational/non-registered product other than the study intervention(s) within 30 days before the first dose/planned use during the study period.
   * Previous and planned vaccination with an OMV based Neisseria meningitidis group B vaccine (e.g., Bexsero, MeNZB vaccine or MenBvac at any time prior to first dose and during the entire study period.
   * Planned administration/administration of a vaccine not specified in study protocol within 15 days before the first dose and ending 15 days after the last dose of vaccine administration.
   * Administration of long-acting immune-modifying drugs during the period starting 6 months prior to the first dose of study intervention/planned administration at any time during the study period.
   * Administration of immunoglobulins /any blood products/plasma derivatives during the period starting 3 months before the administration of the first dose of study intervention/planned administration during the study period.
   * Chronic administration (more than 14 days in total) of immunosuppressants/other immune-modifying drugs during the period starting 3 months prior to the first study intervention dose(s). For corticosteroids, this will mean prednisone equivalent ≥20 mg/day for adult participants/ ≥0.5 mg/kg/day. Inhaled and topical steroids are allowed.

   The following criterion applies only for the PoC part:

   •Chronic/long-term use of systemic antibiotics with an activity against Neisseria gonorrhoeae.
3. Prior/Concurrent clinical study experience applicable for both dose-escalation safety lead-in part and the PoC part Concurrently participating in another clinical study, at any time during the study period, in which the participant has been/will be exposed to an investigational/a non-investigational intervention.
4. Other exclusions applicable for both dose-escalation safety leading part and the PoC part

   * Pregnant/lactating female.
   * Female planning to become pregnant/to discontinue contraceptive precautions before 1 month after completion of the study intervention administration series.
   * Any study personnel/their immediate dependents, family/household members.
   * Lifestyle consideration that may interfere with the conduct of the study/pose additional risks to the rights and wellbeing of participants.

Primary outcomes:
measure: Percentage of participants reporting solicited administration site events in study Phase 1 (Dose-escalation safety lead-in)
timeFrame: During the 7 days follow-up period after the first dose
measure: Percentage of participants reporting solicited administration site events in study Phase 1 (Dose-escalation safety lead-in)
timeFrame: During the 7 days follow-up period after the second dose
measure: Percentage of participants reporting each solicited systemic event in study Phase 1 (Dose-escalation safety lead-in)
timeFrame: During the 7 days follow-up period after the first dose
measure: Percentage of participants reporting each solicited systemic event in study Phase 1 (Dose-escalation safety lead-in)
timeFrame: During the 7 days follow-up period after the second dose
measure: Percentage of participants reporting unsolicited adverse events (AEs) in study Phase 1 (Dose-escalation safety lead-in)
timeFrame: During the 30 days follow-up period after the first dose
measure: Percentage of participants reporting unsolicited AEs in study Phase 1 (Dose-escalation safety lead-in)
timeFrame: During the 30 days follow-up period after the second dose
measure: Percentage of participants reporting serious adverse events (SAEs) in study Phase 1 (Dose-escalation safety lead-in)
timeFrame: From Day 1 after the first dose up to study Phase I end (Day 241)
measure: Percentage of participants reporting AEs leading to withdrawal in study Phase 1 (Dose-escalation safety lead-in)
timeFrame: From Day 1 after the first dose up to study Phase I end (Day 241)
measure: Percentage of participants with haematological and biochemical laboratory abnormalities in study Phase 1 (Dose-escalation safety lead-in)
timeFrame: 7 days after the first dose
measure: Percentage of participants with haematological and biochemical laboratory abnormalities in study Phase 1 (Dose-escalation safety lead-in)
timeFrame: 7 days after the second dose
measure: Incidence rates of confirmed gonorrhea cases in study Phase 2 [Efficacy Proof of Concept (PoC)]
timeFrame: From 1 month to 13 months post-Dose 2
measure: Percentage of participants reporting solicited administration site events in study Phase 2 (Efficacy PoC)
timeFrame: During the 7 days follow-up period after the first dose
measure: Percentage of participants reporting solicited administration site events in study Phase 2 (Efficacy PoC)
timeFrame: During the 7 days follow-up period after the second dose
measure: Percentage of participants reporting each solicited systemic event in study Phase 2 (Efficacy PoC)
timeFrame: During the 7 days follow-up period after the first dose
measure: Percentage of participants reporting each solicited systemic event in study Phase 2 (Efficacy PoC)
timeFrame: During the 7 days follow-up period after the second dose
measure: Percentage of participants reporting unsolicited AEs in study Phase 2 (Efficacy PoC)
timeFrame: During the 30 days follow-up period after the first dose
measure: Percentage of participants reporting unsolicited AEs in study Phase 2 (Efficacy PoC)
timeFrame: During the 30 days follow-up period after the second dose
measure: Percentage of participants reporting SAEs in study Phase 2 (Efficacy PoC)
timeFrame: From Day 1 after the first dose up to study end (Day 451)
measure: Percentage of participants reporting AEs leading to withdrawal in study Phase 2 (Efficacy PoC)
timeFrame: From Day 1 after the first dose up to study end (Day 451)
measure: Percentage of participants with haematological and biochemical laboratory abnormalities in study Phase 2 (Efficacy PoC)
timeFrame: 7 days after the first dose
measure: Percentage of participants with haematological and biochemical laboratory abnormalities in study Phase 2 (Efficacy PoC)
timeFrame: 7 days after the second dose
Secondary outcomes:
measure: Incidence rates of confirmed gonorrhea cases with and without co-infection with a different sexually-transmitted disease causing bacterium in study Phase 2 (Efficacy PoC)
timeFrame: From 1 month to 13 months post-Dose 2
measure: Incidence rates of gonorrhea in study Phase 2 (Efficacy PoC)
timeFrame: From 1 month to 13 months post-Dose 2
measure: Incidence rates of other gonococcal infection with positive Ng in study Phase 2 (Efficacy PoC)
timeFrame: From 1 month to 13 months post-Dose 2
Other outcomes:
Locations:
city: Washington
country: United States
facility: GSK Investigational Site
state: District of Columbia
city: Lenexa
country: United States
facility: GSK Investigational Site
state: Kansas
city: Boston
country: United States
facility: GSK Investigational Site
state: Massachusetts
city: Detroit
country: United States
facility: GSK Investigational Site
state: Michigan
city: Springfield
country: United States
facility: GSK Investigational Site
state: Missouri
city: Bronx
country: United States
facility: GSK Investigational Site
state: New York
city: Austin
country: United States
facility: GSK Investigational Site
state: Texas
city: Salvador
country: Brazil
facility: GSK Investigational Site
state: Bahía
city: Lyon
country: France
facility: GSK Investigational Site
city: Paris Cedex 10
country: France
facility: GSK Investigational Site
city: Pierre-Bénite
country: France
facility: GSK Investigational Site
city: Frankfurt
country: Germany
facility: GSK Investigational Site
state: Hessen
city: Bochum
country: Germany
facility: GSK Investigational Site
state: Nordrhein-Westfalen
city: Hamburg
country: Germany
facility: GSK Investigational Site
city: Manila
country: Philippines
facility: GSK Investigational Site
city: Johannesburg
country: South Africa
facility: GSK Investigational Site
state: Gauteng
city: Soweto
country: South Africa
facility: GSK Investigational Site
state: Gauteng
city: Barcelona
country: Spain
facility: GSK Investigational Site
city: Madrid
country: Spain
facility: GSK Investigational Site
city: Madrid
country: Spain
facility: GSK Investigational Site
city: Valencia
country: Spain
facility: GSK Investigational Site
city: London
country: United Kingdom
facility: GSK Investigational Site
city: London
country: United Kingdom
facility: GSK Investigational Site
Study officials:
References: